Safety and efficacy of vemurafenib in BRAF^V600E and BRAF^V600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Reinhard Dummer, Antoni Ribas, David Hogg, Omid Hamid, Paolo A. Ascierto, Claus Garbe, Alessandro Testori, Michele Maio, Paul Lorigan, Celeste Lebbé, Thomas Jouary, Dirk Schadendorf, Stephen J. O'Day, John M. Kirkwood, Alexander M. EggermontBrigitte Dréno, Jeffrey A. Sosman, Keith T. Flaherty, Ming Yin, Ivor Caro, Suzanne Cheng, Kerstin Trunzer, Axel Hauschild

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

859 Citaten (Scopus)

Sorteer per
Gewicht
Alfabetische volgorde

Safety and efficacy of vemurafenib in BRAF^V600E and BRAF^V600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study

Vingerafdruk

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study

Vingerafdruk

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Safety and efficacy of vemurafenib in BRAF^V600E and BRAF^V600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study